FIELD: medicine; immunology.
SUBSTANCE: invention can be used in treating atypical haemolytic uremic syndrome (aHUS). Use according to the invention involves administering a MASP-2 inhibiting agent, which is an inhibitory anti-MASP-2 monoclonal antibody or antigen-binding fragment thereof, which specifically bind to the human MASP-2 presented as SEQ ID NO: 6, and selectively inhibit MASP-2-dependent complement activation without inhibiting the C1q-dependent complement pathway.
EFFECT: using the invention enables reducing manifestations of symptoms of anemia, thrombocytopenia, renal insufficiency and increasing creatinine.
11 cl, 15 tbl, 36 ex, 45 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR INHIBITING MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2017 |
|
RU2725958C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2718850C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2830289C2 |
| MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING ANTI-C5 CROVALIMAB ANTIBODY | 2020 |
|
RU2832188C2 |
| ANTI-SIGLEC-9 ANTIBODY MOLECULES | 2020 |
|
RU2833330C1 |
| HYBRID PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERED MULTIMERIZED COMPOSITIONS OF IMMUNOGLOBULIN FC REGIONS WITH ENHANCED BINDING WITH A COMPLEMENT SYSTEM | 2016 |
|
RU2737378C2 |
